Intelligent Bio Solutions Inc. - INBS STOCK NEWS

Intelligent Bio Solutions (INBS) announced that Quantum Traffic Management, a UK-based traffic management provider, has implemented INBS' Intelligent Fingerprinting Drug Testing Solution across its 10 nationwide sites. This transition from traditional saliva and urine testing to fingerprint sweat-based drug screening aims to enhance workplace testing efficiency and safety.

Quantum TM joins INBS's portfolio of more than 400 accounts across 19 countries. The fingerprint sweat-based system enables on-site drug screening without specialized staff or facilities, providing rapid results and improved operational efficiency. The company submitted an FDA 510(k) application in December 2024 and plans to enter the US market in 2025.

Intelligent Bio Solutions (INBS) has strengthened its presence in Europe and the Middle East through a partnership with IVY Diagnostics. The collaboration aims to expand the adoption of INBS' Intelligent Fingerprinting Drug Testing Solution, focusing on drug rehabilitation and law enforcement applications.

IVY Diagnostics has secured a tender in Italy to provide INBS' drug screening technology for rehabilitation programs. The solution is also undergoing trials with Turin's local police force for roadside screening. The European drug screening market is projected to reach $3.6 billion by 2030, while the Middle East and Africa market is expected to reach $432.7 million.

IVY Diagnostics serves as INBS' primary European contact, helping expand into Romania, Hungary, Slovakia, Austria, Scandinavia, UAE, Saudi Arabia, and Qatar through its distributor network.

Intelligent Bio Solutions (INBS) announced that Princebuild, a UK construction firm with seven sites, has adopted INBS' Intelligent Fingerprinting Drug Screening System, transitioning from saliva testing to fingerprint drug screening. The system offers a more streamlined, in-house solution prioritizing efficiency, accuracy, and employee privacy.

Princebuild joins INBS' portfolio of over 400 accounts across 19 countries, including notable construction companies like Mount Anvil, Hayfield Homes, Stonbury, MBP Structures, and PJ Hegarty & Sons U.K. The technology is used across multiple industries, including construction, mining, manufacturing, transport, law enforcement, and forensics.

Following its FDA 510(k) submission in December 2024, INBS plans to enter the US market in the first half of 2025, targeting expansion in the drug screening products market.

Intelligent Bio Solutions (INBS) has submitted a 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System, a non-invasive drug testing solution. The system demonstrated 94.1% accuracy in performance studies and showed fingerprint sweat provides reliable drug detection comparable to blood tests at 95% confidence level.

The technology delivers results within 10 minutes through sweat collected from fingertips, targeting safety-critical industries like construction, mining, and transportation, as well as law enforcement and drug rehabilitation sectors. INBS aims to enter the US market in 2025, expanding its presence beyond existing international markets where the system has already proven cost-effective and operationally efficient.

Intelligent Bio Solutions (INBS) has announced a virtual fireside chat scheduled for December 11, 2024, at 4:30 p.m. ET. The event will feature President & CEO Harry Simeonidis and CFO Spiro Sakiris, who will discuss the company's recent clinical study results and their path to FDA 510(k) submission.

The virtual presentation will include a Q&A session for investors, and a recording will be made available on the company's Investor Relations website following the event. Interested participants can register through the provided Zoom webinar link.

Intelligent Bio Solutions (INBS) has successfully completed its method comparison study for the Intelligent Fingerprinting Drug Screening System, achieving 94.1% accuracy, 82.2% sensitivity, and 100% specificity. The study, conducted with CenExel using 135 healthy donors and nine system operators, compared fingerprint sweat opiate screening tests with laboratory LC-MS/MS methods. This milestone, along with recent positive Pharmacokinetic study results, supports INBS's planned FDA 510(k) submission in Q4 2024. If approved, the company aims to launch its non-invasive drug screening technology in the US market in 2025.

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on rapid, non-invasive testing solutions, has announced its participation in the Noble Capital Markets' 20th Annual Emerging Growth Equity Conference. The event will take place on December 3-4, 2024, at Florida Atlantic University in Boca Raton, FL.

The company's management team is scheduled to present on Wednesday, December 4, 2024, at 2:00 p.m. ET in Presentation Room 3. A recording of the presentation will be available on INBS's Investor Relations website two days after the event. The management team will also be available for one-on-one meetings with investors during the conference.

Intelligent Bio Solutions (INBS) announced positive results from its Pharmacokinetic (PK) study, a important step towards FDA 510(k) submission. The study demonstrated that fingerprint sweat effectively mirrors codeine levels in blood and saliva, validating it as a reliable sample matrix for drug detection. The study involved 39 diverse subjects and utilized LC-MS/MS analysis. Statistical comparisons at 95% confidence level showed quantitative PK data closely aligned with blood samples. Upon FDA 510(k) clearance, INBS plans to launch its non-invasive drug screening technology in the US market in 2025, targeting safety-critical industries, law enforcement, and rehabilitation sectors.

Intelligent Bio Solutions (NASDAQ: INBS) reported fiscal Q1 2025 results with total revenue of $0.87 million, up 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of growth. Higher-margin cartridge sales surpassed reader revenue as the primary revenue driver. The company completed the in-clinic portion of its FDA 510(k) clinical study and plans submission by year-end. Net loss increased to $2.70 million from $2.43 million year-over-year, primarily due to R&D investments for FDA studies. Cash position stood at $3.99 million as of September 30, 2024. The company secured 22 new accounts and expanded its distribution network in Saudi Arabia.